CLINICAL HIV AND AIDS JOURNAL
Designation: General Manager
Country: United States
Dr. Yongxin Zhang, CEO of Zyxell Inc., was graduated from Beijing Medical University for both of his MD (1983) and PhD (1989), and received postdoctoral training in Baylor College of Medicine (1996-2004). He has the expertise in the research of immunology, including cancer immune therapy, infection immunology, transplantation immunology and Aging immunology. He worked on cancer vaccines, virus vaccines and bacteria vaccines for over 20 years. His research work on aging immunology revealed the mechanism of the compromised immune responses in aged subjects and exhibited the preventive effects of ex vivo reactivated and expanded lymphocytes on influenza virus infection in aged animals. He is also the inventor of ZYX Bioreactor, which has great advantages in expansion of immunocytes and hematopoietic stem cells over other systems.
- Vaccine research and development
- Cancer therapy with in vitro expanded CTL and NK cell transfusion
- Application of expanded immunocyte transfusion in immune deficiency
Open Access Journals
Subscribe to our Newsletter
Enter your e-mail address to stay informed about published articles, issue releases and latest updates on journal activities.
We openly welcome feedback and constructive criticism. Your compliments, concerns and suggestions regarding our services will prove enormously helpful in making them even better.
Do you have an idea or suggestion that can influence the Open Access community? Send an email to: email@example.com
Recently Released Issues
Copyright © 2020 Boffin Access Limited.